Visit Patient Site
Contact Abbott
English
Get Support Kit
EasyToFreeStyle Sign-Up
Get Support Kit

Better outcomes. Clinically proven in patients with T1D and T2D.1-11*

Both real-world evidence and clinical trial results show improved outcomes with the FreeStyle Libre 2 system.1,4-10*

Proven outcomes

Associated with a 0.9% reduction in A1C5* (p<0.0001)


T2D real-world study results: 

  • Patients on long-acting (basal) insulin:6*† 

    • Associated with a 1.1% reduction in A1C (from 10.1% at baseline to 9.0%; p<0.001)

  • Patients on non-insulin therapies:6*‡

    • Associated with a 1.6% reduction in A1C (from 10.1% at baseline to 8.5%; p<0.001)

  • Patients with poor glycemic control (baseline A1C ≥12%):6*§

    • Associated with a 3.7% reduction in A1C (from 13.1% at baseline to 9.4%; p<0.001)

Associated with a 43% increase in time in target range

(3.9-10.0 mmol/L) from 11.7 to 16.8 hours a day with increased scan rate7*  
(p<0.001) 

Associated with a 63% reduction in time spent above 13.3 mmol/L

across patients with diabetes7* (p<0.001) 

Associated with a 43% reduction in time spent <3.9 mmol/L

in patients with T2D8* (p<0.001) 

Patients with T1D and T2D using the system:9*

  • 95% report a better understanding of their glucose fluctuations

  • 92% find it easier to regulate their glucose around a meal

0.4% reduction in A1C10*¶ 

Increased time in target range by 1 hour/day11* 

(3.9-10.0 mmol/L) 

Reduced time spent in hyperglycemia (>10 mmol/L) by 1 hour/day

with no significant increase in time spent in hypoglycemia (<3.9 mmol/L).10,11*¶ 

Increased the frequency of glucose monitoring to an average of 8x per day

vs. CBG.10*

Increased monitoring means improved self-management8,11-13

Clinically proven accuracy14

Demonstrated accuracy vs. YSI analyzer reference values15

Consensus error grid shows the FreeStyle Libre system delivers proven accuracy15

9.5%

Overall MARD16

The lower the MARD, the more accurate the results 

Measurement errors associated with these zones have no effect on clinical action, and little or no effect on clinical outcomes.4

Trusted accuracy: Replaces
CBG, including insulin dosing.**  

Excellent accuracy at a glance

9.2%

Overall MARD17

The lower the MARD, the more accurate the results 

99.9%

in zones A+B  

of consensus error grid14

Measurement errors associated with these zones have no effect on clinical action, and little or no effect on clinical outcomes.4*

Trusted accuracy, even when glucose is low, falling or rapidly changing.14

Outstanding accuracy in the low glucose range14

  • Outstanding accuracy in the Low glucose range (<3.9 mmol/L)14

  • 98.4% of results for levels <3.9 mmol/L are within ±1.1 mmol/L of blood glucose measurements14

Clinically proven to be accurate14 over 14 days in pediatric patients††

9.7%

Overall MARD

The lower the MARD, the more accurate the results14

100%

in zones A+B  

of consensus error grid14

Measurement errors associated with these zones have no effect on clinical action, and little or no effect on clinical outcomes.4*

Outstanding low-end accuracy where it matters most14**††

  • Low glucose range (<3.9 mmol/L)

  • 98.8% of results in this range are within ±1.1 mmol/L of blood glucose measures14

Parents and caregivers can rely on the FreeStyle Libre 2 system to make treatment decisions** even when glucose is low, falling or rapidly changing.14

CBG=capillary blood glucose; MARD=mean absolute relative difference; YSI=Yellow Springs Instrument.

* Data collected from the FreeStyle Libre system. FreeStyle Libre 2 has the same features as the FreeStyle Libre system, with the addition of optional real-time glucose alarms. Study data are applicable to both products.

† Real-world data on change in A1C in patients with T2D taking long-acting insulin therapy after use of the FreeStyle Libre system for 6 months (n=277) and 12 months (n=87). In the 12-month group, patients using the FreeStyle Libre system demonstrated significant A1C reduction of 0.5% (p=0.0014).

‡ Real-world data on change in A1C in patients with T2D taking non-insulin therapies (oral agents, GLP-1 receptor agonists) after use of the FreeStyle Libre system for 6 months (n=497) and 12 months (n=120). In the 12-month group, patients using the FreeStyle Libre system demonstrated significant A1C reduction of 0.7% (p<0.0001).

§ Real-world data on change in A1C in 1,183 patients with T2D and poor glycemic control not on bolus insulin after use of the FreeStyle Libre system for 6 months. 

¶ Results from the SELFY study of diabetes self-management in children (4-12 years) and teenagers (13-17 years). Questionnaire was completed by either children or their caregiver. 

** Treatment decisions should not be based on real-time readings alone but instead should consider all the information on the results screen.

†† All values vs. YSI.

 

References:

  1. Berard L, et al. Canadian real-world analysis of flash glucose monitoring and impact on glycemic control. Poster presented at: Diabetes Canada Conference; October 2-5, 2019; Winnipeg, MB.
  2. Dunn TC, et al. Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: A European analysis of over 60 million glucose tests. Diabetes Res Clin Pract 2018;137:37-46.
  3. Yaron M, et al. Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes. Diabetes Care 2019;42(7):1178-84.
  4. Data on file, Abbott Diabetes Care Inc.
  5. Kröger J, et al. Three European retrospective real-world chart review studies to determine the effectiveness of flash glucose monitoring on HbA1c in adults with type 2 diabetes. Diabetes Ther 2020;11(1):279-91.
  6. Wright EE Jr, et al. Use of flash glucose monitoring is associated with A1C reduction in people with type 2 diabetes treated with basal insulin or noninsulin therapy. Diabetes Spectr 2021;34(2):184-89.
  7. Lang J, et al. Expanded real-world use confirms strong association between frequency of flash glucose monitoring and glucose control [Abstract 089]. Diabetes Technol Ther 2019;21(1):A40.
  8. Haak T, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 2017;8(1):55-73.
  9. Fokkert M, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diabetes Res Care 2019;7(1):e000809. 
  10. Campbell FM, et al. Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study. Pediatr Diabetes 2018;19(7):1294-301.
  11. Bolinder J, et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 2016;388(10057):2254-63.
  12. Ajjan R. Insights from real world use of flash continuous glucose monitoring. Symposium presented at: American Diabetes Association 78th Scientific Sessions; June 22-26, 2018; Orlando, FL.
  13. Leelarathna L, et al. Intermittently scanned continuous glucose monitoring for type 1 diabetes. N Engl J Med 2022;387(16):1477-1487.
  14. Alva S, et al. Accuracy of a 14-day factory-calibrated continuous glucose monitoring system with advanced algorithm in pediatric and adult population with diabetes. J Diabetes Sci Technol 2020
  15. Bailey T, et al. The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther 2015;17(11):787-94.
  16. FreeStyle Libre Flash Glucose Monitoring System User’s Manual.
  17. FreeStyle Libre 2 Flash Glucose Monitoring System User’s Manual.

This site is intended for Canadian Healthcare Professionals only. Visit patient site.

The FreeStyle Libre flash glucose monitoring system is indicated for measuring interstitial fluid glucose levels in adults aged 18 years and older with diabetes mellitus. Always read and follow the label/insert. 

The FreeStyle Libre 2 flash glucose monitoring system is indicated for measuring interstitial fluid glucose levels in people aged 4 years and older with diabetes mellitus. Always read and follow the label/insert.

Why Continuous Glucose Monitoring?
About FreeStyle Libre
How to Prescribe
LibreView
Clinic Resources
Abbott. life. to the fullest

© 2023 Abbott
The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Product images are for illustrative purposes only. Other trademarks are the property of their respective owners.
ADC-64590 v3.0

You’re now leaving an Abbott Canada website, a site maintained by Abbott

You are now being redirected to a third-party website not under the control of Abbott. Abbott is not responsible for the contents of such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply the endorsement of the linked site by Abbott.

Do you wish to leave this site?

Disclaimer

EasytoFreeStyle.ca is a product-specific website intended only for residents of Canada.

If you are a resident of another country, please visit our global directory to locate the appropriate site for your country.